These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 25959589

  • 1. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F.
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [Abstract] [Full Text] [Related]

  • 2. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B, Tönshoff B.
    Paediatr Drugs; 2011 Feb 01; 13(1):49-69. PubMed ID: 21162600
    [Abstract] [Full Text] [Related]

  • 3. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A, Diekmann F, Revuelta I, Esforzado N, Ricart MJ, Cofán F, Torregrosa JV, Peri L, Ruiz Á, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Mar 01; 29(3):362-8. PubMed ID: 26678359
    [Abstract] [Full Text] [Related]

  • 4. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
    Kälble F, Schaier M, Schäfer S, Süsal C, Zeier M, Sommerer C, Morath C.
    Expert Opin Pharmacother; 2017 Jun 01; 18(8):799-807. PubMed ID: 28460546
    [Abstract] [Full Text] [Related]

  • 5. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X, Jiang Y, Lai X, Xiang S, Shou Z, Chen J.
    BMC Nephrol; 2015 Jul 01; 16():91. PubMed ID: 26126806
    [Abstract] [Full Text] [Related]

  • 6. Calcineurin-inhibitor-sparing immunosuppressive protocols.
    Bestard O, Cruzado JM, Grinyó JM.
    Transplant Proc; 2005 Nov 01; 37(9):3729-32. PubMed ID: 16386520
    [Abstract] [Full Text] [Related]

  • 7. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov 01; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 8. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B.
    Transplantation; 2018 Feb 01; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [Abstract] [Full Text] [Related]

  • 9. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
    Kamar N, Del Bello A, Belliere J, Rostaing L.
    Transpl Int; 2015 Aug 01; 28(8):928-37. PubMed ID: 25557802
    [Abstract] [Full Text] [Related]

  • 10. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A, Osorio-Jaramillo E, Aliabadi-Zuckermann AZ.
    Transplantation; 2018 Feb 01; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [Abstract] [Full Text] [Related]

  • 11. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B.
    Clin Transplant; 2013 Feb 01; 27 Suppl 25():16-29. PubMed ID: 23909498
    [Abstract] [Full Text] [Related]

  • 12. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N.
    Am J Kidney Dis; 2017 May 01; 69(5):587-594. PubMed ID: 27889299
    [Abstract] [Full Text] [Related]

  • 13. Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2.
    Wojciechowski D, Vincenti F.
    Adv Chronic Kidney Dis; 2016 Sep 01; 23(5):306-311. PubMed ID: 27742385
    [Abstract] [Full Text] [Related]

  • 14. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P, Campistol JM, Diekmann F.
    Expert Opin Drug Saf; 2016 Sep 01; 15(3):303-19. PubMed ID: 26667069
    [Abstract] [Full Text] [Related]

  • 15. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A, Tordera D, de la Sen ML, Jiménez L, Mas P, Muñoz C, Olivares J.
    Nefrologia; 2012 Sep 01; 32(5):631-8. PubMed ID: 23013949
    [Abstract] [Full Text] [Related]

  • 16. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan 01; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 17. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
    Kirk AD, Guasch A, Xu H, Cheeseman J, Mead SI, Ghali A, Mehta AK, Wu D, Gebel H, Bray R, Horan J, Kean LS, Larsen CP, Pearson TC.
    Am J Transplant; 2014 May 01; 14(5):1142-51. PubMed ID: 24684552
    [Abstract] [Full Text] [Related]

  • 18. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I, Chan L.
    Transplant Proc; 2011 Mar 01; 43(2):472-7. PubMed ID: 21440737
    [Abstract] [Full Text] [Related]

  • 19. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Mar 01; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 20. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators.
    Lancet; 2011 Mar 05; 377(9768):837-47. PubMed ID: 21334736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.